Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus - Yahoo Finance
Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus - Yahoo Finance(摘要待生成)
Lucid Capital raised its HELP target to $79 from $52 and retained Buy
On Nov. 16, 2026, Lucid Capital raised its price target to $79 from $52, kept Buy, and increased its HLP003 probability-of-success estimate to 70% from 45% after APPROACH results. The firm attributed the day’s share-price selloff to investor misunderstanding of the treatment modality and indication.
Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump - Reuters
Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump Reuters
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study of HLP003
Helus Pharma announced it will host a webcast on November 16, 2026, to reveal topline results from its Phase 3 APPROACH clinical trial evaluating HLP003 as an adjunctive treatment for major depressive disorder.
Helus Pharma reported fiscal Q2 2027 results and business updates
On Nov. 16, 2026, Helus reported $171.1 million cash as of Sept. 30, 2026; quarterly net loss was $103.1 million vs. $33.7 million a year earlier, and operating cash use was $35.3 million vs. $34.5 million. It appointed Michael Halstead CEO, reported APPROACH enrollment complete, and said the HLP004 Phase 2 GAD study is expected to start Q1 2027, enrolling about 144 participants.
Helus Pharma announced positive Phase 3 APPROACH results for HLP003
On Nov. 16, 2026, Helus reported Phase 3 results in 222 adults with MDD: at Week 6, MADRS fell 19.5 points with HLP003 vs. 11.9 with placebo (difference −7.6; p<0.0001; effect size 0.653); at Week 12, difference was −7.0 (p<0.0001). Response at Week 6: 56.3% vs. 28.2%; remission: 50.9% vs. 18.2%. Three treatment-related serious adverse events; no new safety signals. EMBRACE topline expected 4Q 202